1436686-17-7

Basic information

• Product Name: ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate
• Synonyms: ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate;5-Bromo-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester
• CAS NO: 1436686-17-7
• Molecular Formula: C₉H₈BrN₃O₂
• Molecular Weight: 270.08272
• Mol File: 1436686-17-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate(1436686-17-7)
• EPA Substance Registry System: ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate(1436686-17-7)

Safety Data

• Hazardous Substances Data: 1436686-17-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
Ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate serves as a key component in the development of new drugs and pharmaceutical products due to its potential medicinal properties. It is employed as a precursor in the synthesis of various bioactive compounds, contributing to the advancement of novel therapeutic agents.
Used in Organic Synthesis:
As a building block in organic synthesis, ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate is utilized to construct complex organic molecules. Its unique structure allows for the formation of diverse chemical entities, facilitating the synthesis of a wide range of compounds with potential applications in various fields.
Used in Chemical and Biological Studies:
Ethyl 5-bromopyrazolo[1,5-a]pyrimidine-3-carboxylate also functions as a research tool in chemical and biological studies. It aids in understanding the structure-activity relationships of pyrazolopyrimidine derivatives and their potential applications in medicinal chemistry. Additionally, it provides insights into the biological activities and mechanisms of action of these compounds, paving the way for the discovery of new therapeutic agents.

Upstream product

• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 
• 94-05-3 2-cyano-3-ethoxyacrylic acid ethyl ester 
• 105-56-6 ethyl 2-cyanoacetate 
• 926663-00-5 5-hydroxypyrazole[1,5-a]pyrimidine-3-carboxylic acid ethyl ester 

Downstream Products

• 1449426-10-1 C₃₂H₃₃F₂N₇O₃ 
• 1436685-68-5 N-(5-(2,6-difluorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-(2-(piperidin-4-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide 

Relevant articles and documents

MACROCYCLIC COMPOUNDS AS TRK KINASE INHIBITORS AND USES THEREOF

The present disclosure describes novel TRK kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such TRK kinase inhibitors and methods of using them for treating cancer, infectious diseases, and other disorders are also described.

Substituted heteroaryl compounds and compositions and uses thereof

The invention discloses a substituted ceteroary compound as well as a composition and an application thereof. The compound is a compound shown in a formula (I) or a stereisomer, a tautomer, a nitric oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The invention further discloses a pharmaceutical composition including the compound. The compound and the pharmaceutical composition are capable of adjusting the activity of the AK kinase and can be used for preventing, processing, treating and relieving the JAK-mediated disease or disorder.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heterocyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design

Pim kinases are promising targets for the development of cancer therapeutics. Among the three Pim isoforms, Pim-2 is particularly important in multiple myeloma, yet is the most difficult to inhibit due to its high affinity for ATP. We identified compound 1 via high throughput screening. Using property-based drug design and co-crystal structures with Pim-1 kinase to guide analog design, we were able to improve potency against all three Pim isoforms including a significant 10,000-fold gain against Pim-2. Compound 17 is a novel lead with low picomolar potency on all three Pim kinase isoforms.